Fig. 1

Venetoclax and Daratumumab inhibit AML cell growth. a Primary AML and CD34 + flow cytometry analysis for CD38 and BCL-2 expression as assessed by MFI (n = 7). b Primary AML (#1–6) were cultured together for 24 h in the presence of varying concentrations of Venetoclax alone or Daratumumab alone. Cell viability was assessed by CellTiter-Glo (n = 6) and expressed as a percentage compared to control untreated cells. c Primary AML were cultured together for 24 h in the presence of Venetoclax and varying concentrations of Daratumumab. Cell viability was assessed by CellTiter-Glo (n = 3). d and e Primary AML (#1, #2, #3, #7 and #9) and MSC cultured together for 24 h in the presence of vehicle, Venetoclax (100nm) alone or Daratumumab (100ng/ml) alone or Venetoclax and Daratumumab in combination. Primary AML were then stained with Annexin V/PI, flow cytometry was used to detect cell death (n = 5). Statistical tests used were Mann-Whitney U test (A) or Kruskal-Wallis statistical test followed by Dunn’s multiple comparisons (b-e). Data shown are means ± SD *P < 0.05 **P < 0.01